Study: NCT04870138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA1090 A26
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA1090 A26
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA7527
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA7527
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.